Navigation Links
Precision Therapeutics Announces New Tumor Profiling Product to Augment Utility of ChemoFx® and Further Personalize Cancer Treatment
Date:4/7/2011

PITTSBURGH, April 7, 2011 /PRNewswire/ -- Precision Therapeutics, Inc. announced that the launch of a new product line, BioSpeciFx®, will help further the personalization of cancer treatments.  BioSpeciFx® is composed of carefully selected sets of well validated and clinically useful biomarker tests that identify critical molecular targets within a patient's cell.  By using the information generated by BioSpeciFx® in combination with Precision's sophisticated drug response marker ChemoFx®, physicians may gain a more complete understanding of a patient's tumor.

When combined, both products offer a complementary sum of information which will enable physicians to look at both the relevant molecular targets as well as the synergistic activity of drug combinations on the entire cell.  BioSpeciFx® provides proteomic and genomic information, while ChemoFx® takes into account all of the functional characteristics of a tumor including those not captured by biomarker testing, providing both sensitivity and resistance information.

"The Comprehensive Tumor Profile developed by Precision presents the most complete offering available to cancer patients today, because it integrates both genomic and proteomic information with the functional profiling of ChemoFx®," says Sean McDonald, CEO of Precision Therapeutics.  "We are very excited to provide physicians with a closer look at each patient's tumor as we continue to develop products aimed at personalizing treatments for cancer patients."

About Precision Therapeutics

Precision Therapeutics, a life-science company based in Pittsburgh, Pennsylvania, is committed to improving outcomes of cancer patients.  As leaders in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer.  

Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy. 

ChemoFx® is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician.  Precision currently receives ChemoFx® specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. To date, ChemoFx® Final Reports have been provided for over 56,000 patient specimens, using 105 unique chemotherapy treatments and combinations.

For more information, visit www.precisiontherapeutics.com or www.chemofx.com.


'/>"/>
SOURCE Precision Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Precision Therapeutics Announces Two Pancreatic Cancer Studies Emphasizing the Utility of ChemoFx® in Cancer Treatment Options
2. Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year
3. Applied Precision Installs New DeltaVision
4. OMX® Super-Resolution Imaging System in the Light Microscopy Imaging Center at Indiana University
5. Pinpoint precision: Delivering a biochemical payload to 1 cell
6. Precision Therapeutics Growing Rapidly as it Augments Research and Development Efforts
7. Stretching single molecules allows precision studies of interacting electrons
8. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
9. Precision Therapeutics Named to Inc. Magazines List of Fastest Growing Companies
10. New statistical technique improves precision of nanotechnology data
11. Precision Stability Storage Announces Upcoming Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016  The Board of Directors of the ... Western Pennsylvania,s only pure life sciences investment ... with the succession plan developed by the Nominating and ... James (Jim) F. Jordan is selected to ... John W. Manzetti , who is elected to the ...
(Date:12/8/2016)... ... December 08, 2016 , ... From wearable devices that can ... sports. On Thursday, December 15th a panel of entrepreneurs, innovators and a Philadelphia ... at a Smart Talk session. Smart Talk will run from 8:30 – 10:30 ...
(Date:12/8/2016)... DES MOINES, Iowa , Dec. 8, 2016 Eurofins ... for US Food and President of Eurofins Scientific Inc. (ESI). ... Food Division with his proven professional and entrepreneurial experience in leading ... growth in the US food testing market to uphold Eurofins, status ... ...
(Date:12/8/2016)... , December 8, 2016 ... expanded its customisable SureSeq™ NGS panel range with the launch ... fast and cost-effective study of variants in familial hypercholesterolemia (FH). ... variation (CNV) detection on a single small panel and allows ... content. This includes all exons for LDLR , ...
Breaking Biology Technology:
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
(Date:11/22/2016)... , November 22, 2016 According to the new ... Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function ... by MarketsandMarkets, the market is expected to grow from USD 10.74 Billion ... of 16.79% between 2016 and 2022. Continue ... ...
(Date:11/17/2016)... LONDON , Nov. 17, 2016 Global Market ... and Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market ... Geographical analysis for Private Biobanks shows the highest Compounded Annual ... Asia-Pacific region during the analysis period 2014-2020. ... a CAGR of 9.95% followed by Europe ...
Breaking Biology News(10 mins):